Hoppe Ann-Kathrin, Li Suzanne C, Foeldvari Ivan
Semmelweis University, Üllői út 26, 1086, Budapest, Hungary.
Department of Pediatrics, Division of Pediatric Rheumatology, Hackensack Meridian School of Medicine, 07601, Hackensack, NJ, USA.
Z Rheumatol. 2024 Apr;83(3):194-199. doi: 10.1007/s00393-022-01296-0. Epub 2022 Dec 15.
Localized scleroderma is an autoimmune disease belonging to the group of collagenoses, which can manifest cutaneously and extracutaneously. The extracutaneous manifestations may have significant morbidity but are not considered in previous scoring systems. For this reason, another scoring system, the total morbidity score (TMS) was developed, which also takes into account the extracutaneous symptoms.
In the retrospective monocentric study at the Hamburg Center for Pediatric and Adolescent Rheumatology, the TMS was applied to patients from 2004-2019 suffering from localized scleroderma who had at least one control presentation. In addition, data were analyzed according to the previously established localized scleroderma cutaneous assessment tool (LoSCAT) scoring systems to ensure better comparability to the TMS. Furthermore, the score values were considered and compared during the course of treatment with methotrexate (MTX).
Due to a lack of control presentations, data from 51 of the 95 patients with a confirmed diagnosis could be included in the retrospective evaluation. The treatment of these patients was considered over a period of 2 years, from the initial presentation over at least 3 further control presentations. The TMS total score remained largely constant. There was a weak correlation between the TMS total score and the localized scleroderma skin damage index (mLoSDI), which indicates the degree of damage. In addition, insignificant changes in the TMS total score were shown over time with MTX treatment (T1/T4: -0.007).
The evaluation showed that the TMS total score is mainly fed by the extracutaneous manifestations, demonstrating the inaccuracy of previous scores. Another advantage of the TMS is that different scores are assigned depending on whether the feature is new, persistent, improving, or even worsening. The TMS is more time consuming to collect but enables a more accurate assessment of disease activity.
局限性硬皮病是一种属于胶原病的自身免疫性疾病,可表现为皮肤症状和皮肤外症状。皮肤外表现可能具有显著的发病率,但在以前的评分系统中未被考虑。因此,开发了另一种评分系统,即总发病率评分(TMS),该系统也考虑了皮肤外症状。
在汉堡儿童和青少年风湿病中心进行的回顾性单中心研究中,将TMS应用于2004年至2019年患有局限性硬皮病且至少有一次对照就诊的患者。此外,根据先前建立的局限性硬皮病皮肤评估工具(LoSCAT)评分系统对数据进行分析,以确保与TMS有更好的可比性。此外,在使用甲氨蝶呤(MTX)治疗过程中对评分值进行了考虑和比较。
由于缺乏对照就诊,95例确诊患者中的51例数据可纳入回顾性评估。这些患者的治疗时间为2年,从初次就诊开始,至少经过3次进一步的对照就诊。TMS总分基本保持不变。TMS总分与局限性硬皮病皮肤损伤指数(mLoSDI)之间存在弱相关性,mLoSDI表明损伤程度。此外,MTX治疗期间TMS总分随时间变化不显著(T1/T4:-0.007)。
评估表明,TMS总分主要受皮肤外表现影响,这表明先前评分的不准确。TMS的另一个优点是,根据特征是新出现、持续、改善还是恶化,会分配不同的分数。收集TMS更耗时,但能更准确地评估疾病活动。